| 초록 |
Tumor cell receptor binding peptides (affibody and/or RGD-derived peptides, named 4CRGD) are presented on the surface of human ferritin heavy-chain nanoparticle (hFTH). The 4CRGD and affibody specifically binds to tumor cell receptor, integrin αvβ3 and epidermal growth factor receptor Ⅰ(EGFR), respectively. Through in vitro cultures of integrin-overexpressing glioblastoma cells (U87MG) and EGFR-overexpressing adenocarcinoma (MDA-MB-468), specific interaction between tumor cell receptors and receptor binding peptides on the surface of recombinant hFTHs is clarified. Then each recombinant hFTHs are labeded with near-infrared fluoresence dye (Cy5.5) and intravenously injected into MDA-MB-468 or U87MG bearing mice, Cy5.5-labeled recombinant hFTHs are successfully delivered to and retained in the tumor. And both affibody and 4CRGD-presenting hFTH notably enhances in vivo detection of U87MG tumors that express EGFR and integrin, compared to the other recombinant hFTHs. |
